Immix Biopharma Stock Buy Hold or Sell Recommendation
| IMMX Stock | USD 1.97 0.09 4.37% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Immix Biopharma is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Immix Biopharma given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Immix Biopharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Immix Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide. In addition, we conduct extensive research on individual companies such as Immix and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Immix Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Immix |
Execute Immix Biopharma Buy or Sell Advice
The Immix recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immix Biopharma. Macroaxis does not own or have any residual interests in Immix Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immix Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Immix Biopharma Trading Alerts and Improvement Suggestions
| Immix Biopharma is way too risky over 90 days horizon | |
| Immix Biopharma may become a speculative penny stock | |
| Immix Biopharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (15.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immix Biopharma currently holds about 18.4 M in cash with (11.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Marquet Magda of 10000 shares of Immix Biopharma at 2.4722 subject to Rule 16b-3 |
Immix Biopharma Returns Distribution Density
The distribution of Immix Biopharma's historical returns is an attempt to chart the uncertainty of Immix Biopharma's future price movements. The chart of the probability distribution of Immix Biopharma daily returns describes the distribution of returns around its average expected value. We use Immix Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immix Biopharma returns is essential to provide solid investment advice for Immix Biopharma.
| Mean Return | 0.50 | Value At Risk | -8.19 | Potential Upside | 9.38 | Standard Deviation | 5.97 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immix Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Immix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Immix Biopharma, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Immix Biopharma back and forth among themselves.
| Shares | Fny Investment Advisers, Llc | 2024-06-30 | 32.5 K | Invst Llc | 2024-09-30 | 27 K | Commonwealth Equity Services Inc | 2024-09-30 | 26.1 K | Millennium Management Llc | 2024-09-30 | 21.5 K | Blackrock Inc | 2024-09-30 | 14 K | The Colony Group Llc | 2024-09-30 | 11.9 K | Old National Bancorp | 2024-09-30 | 10 K | Ubs Group Ag | 2024-09-30 | 6.1 K | Tower Research Capital Llc | 2024-09-30 | 3.1 K | Aigh Capital Management, Llc | 2024-09-30 | 1.1 M | Bleichroeder Lp | 2024-09-30 | 850 K |
Immix Biopharma Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (342.9K) | 17.3M | (4.2M) | 4.1M | 4.7M | 3.8M | |
| Free Cash Flow | (404.7K) | (1.6M) | (7.4M) | (11.4M) | (10.3M) | (9.8M) | |
| Depreciation | 2.3K | 2.5K | 2.1K | 5.5K | 6.3K | 6.6K | |
| Other Non Cash Items | 575K | 118.2K | 100K | 2.3M | 2.6M | 2.7M | |
| Net Income | (1.1M) | (24.4M) | (8.2M) | (15.6M) | (14.0M) | (14.7M) | |
| End Period Cash Flow | 391.1K | 17.6M | 13.4M | 17.5M | 20.1M | 10.9M |
Immix Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immix Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immix Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immix stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.48 | |
β | Beta against Dow Jones | 0.05 | |
σ | Overall volatility | 6.25 | |
Ir | Information ratio | 0.07 |
Immix Biopharma Volatility Alert
Immix Biopharma exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immix Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immix Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Immix Biopharma Fundamentals Vs Peers
Comparing Immix Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immix Biopharma's direct or indirect competition across all of the common fundamentals between Immix Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immix Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immix Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Immix Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Immix Biopharma to competition |
| Fundamentals | Immix Biopharma | Peer Average |
| Return On Equity | -1.04 | -0.31 |
| Return On Asset | -0.57 | -0.14 |
| Current Valuation | 38.06 M | 16.62 B |
| Shares Outstanding | 27.51 M | 571.82 M |
| Shares Owned By Insiders | 40.09 % | 10.09 % |
| Shares Owned By Institutions | 17.64 % | 39.21 % |
| Number Of Shares Shorted | 378.86 K | 4.71 M |
| Price To Book | 3.23 X | 9.51 X |
| EBITDA | (16.14 M) | 3.9 B |
| Net Income | (15.6 M) | 570.98 M |
| Cash And Equivalents | 18.4 M | 2.7 B |
| Cash Per Share | 1.32 X | 5.01 X |
| Total Debt | 3.72 M | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 19.53 X | 2.16 X |
| Book Value Per Share | 0.82 X | 1.93 K |
| Cash Flow From Operations | (11.37 M) | 971.22 M |
| Short Ratio | 2.94 X | 4.00 X |
| Earnings Per Share | (0.84) X | 3.12 X |
| Target Price | 7.0 | |
| Number Of Employees | 14 | 18.84 K |
| Beta | 0.1 | -0.15 |
| Market Capitalization | 54.19 M | 19.03 B |
| Total Asset | 19.93 M | 29.47 B |
| Retained Earnings | (53.41 M) | 9.33 B |
| Working Capital | 16.07 M | 1.48 B |
| Net Asset | 19.93 M |
Note: Acquisition by Marquet Magda of 10000 shares of Immix Biopharma at 2.4722 subject to Rule 16b-3 [view details]
Immix Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immix . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 3956.75 | |||
| Daily Balance Of Power | (0.90) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 2.01 | |||
| Day Typical Price | 2.0 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.09) |
About Immix Biopharma Buy or Sell Advice
When is the right time to buy or sell Immix Biopharma? Buying financial instruments such as Immix Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Immix Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.